Suppr超能文献

急性肾损伤分期预测体外膜肺氧合支持患者的预后。

Acute kidney disease stage predicts outcome of patients on extracorporeal membrane oxygenation support.

机构信息

Department of Nephrology, Chang Gung Memorial Hospital, Keelung, Taiwan.

College of Medicine, Chang Gung University, Taoyuan, Taiwan.

出版信息

PLoS One. 2020 Apr 8;15(4):e0231505. doi: 10.1371/journal.pone.0231505. eCollection 2020.

Abstract

BACKGROUND

The mortality rate of patients on extracorporeal membrane oxygenation (ECMO), especially those patients that develop acute kidney injury (AKI) is high. Acute kidney disease (AKD) is a term used to describe the continuum from AKI to chronic kidney disease. However, the role of AKD in predicting the prognosis of patients on ECMO support is unclear.

METHODS

A total of 168 patients who received ECMO support and survived for more than 7 days at a single hospital from 2003 to 2008 were enrolled for this study and followed up for 10 years or till mortality. Kaplan-Meier analysis and Cox proportional hazards model were used to determine the prognostic factors associated with survival.

RESULTS

The median survival times of patients with stage 0, stage 1, stage 2 and stage 3 AKD were ≥ 10 years, 43.9 months, 1 month, and half a month, respectively. There were statistically significant differences in cumulative survival rate between patients with stage 3 AKD and those with stage 0, 1, and 2 AKD (Cox-Mantel log rank test, p<0.001, p<0.001, p = 0.023), and between patients with stage 0 AKD and those with stage 1 and 2 AKD (Cox-Mantel log rank test, p = 0.012, p<0.001). Cox regression analysis revealed that AKD stage (hazard ratio [HR]: 2.576, 95% confidential interval [CI]: 1.268-5.234, p = 0.009 for stage 1; HR: 2.349; 95% CI: 1.101-5.512, p = 0.029 for stage 2; HR: 5.252; 95% CI: 2.715-10.163, p<0.001 for stage 3) was significant independent predictor of survival.

CONCLUSION

AKD stage is an independent predictor of survival in patients on ECMO support.

摘要

背景

体外膜肺氧合(ECMO)患者,尤其是发生急性肾损伤(AKI)的患者,死亡率较高。急性肾脏病(AKD)是一个用来描述从 AKI 到慢性肾脏病的连续过程的术语。然而,AKD 在预测 ECMO 支持患者预后中的作用尚不清楚。

方法

本研究纳入了 2003 年至 2008 年在一家医院接受 ECMO 支持并存活超过 7 天的 168 例患者,并进行了 10 年或直至死亡的随访。采用 Kaplan-Meier 分析和 Cox 比例风险模型确定与生存相关的预后因素。

结果

AKD 0 期、1 期、2 期和 3 期患者的中位生存时间分别为≥10 年、43.9 个月、1 个月和半个月。AKD 3 期患者的累积生存率与 AKD 0 期、1 期和 2 期患者之间存在统计学差异(Cox-Mantel 对数秩检验,p<0.001,p<0.001,p=0.023),与 AKD 0 期患者与 AKD 1 期和 2 期患者之间也存在统计学差异(Cox-Mantel 对数秩检验,p=0.012,p<0.001)。Cox 回归分析显示,AKD 分期(危险比[HR]:2.576,95%置信区间[CI]:1.268-5.234,p=0.009 分期 1;HR:2.349;95%CI:1.101-5.512,p=0.029 分期 2;HR:5.252;95%CI:2.715-10.163,p<0.001 分期 3)是 ECMO 支持患者生存的独立显著预测因素。

结论

AKD 分期是 ECMO 支持患者生存的独立预测因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7e8e/7141841/586b5513291d/pone.0231505.g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验